Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera von Vannucchi, Alessandro M, Kiladjian, Jean Jacques, Griesshammer, Martin, Masszi, Tamas, Durrant, Simon, Passamonti, Francesco, Harrison, Claire N, Pane, Fabrizio, Zachee, Pierre, Mesa, Ruben, He, Shui, Jones, Mark M, Garrett, William, Li, Jingjin, Pirron, Ulrich, Habr, Dany, Verstovsek, Srdan

Volltext

Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial von Verstovsek, Srdan, Vannucchi, Alessandro M, Griesshammer, Martin, Masszi, Tamas, Durrant, Simon, Passamonti, Francesco, Harrison, Claire N, Pane, Fabrizio, Zachee, Pierre, Kirito, Keita, Besses, Carlos, Hino, Masayuki, Moiraghi, Beatriz, Miller, Carole B, Cazzola, Mario, Rosti, Vittorio, Blau, Igor, Mesa, Ruben, Jones, Mark M, Zhen, Huiling, Li, Jingjin, Francillard, Nathalie, Habr, Dany, Kiladjian, Jean-Jacques

Volltext

The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double‐blind, double‐dummy, symptom... von Mesa, Ruben, Vannucchi, Alessandro M., Yacoub, Abdulraheem, Zachee, Pierre, Garg, Mamta, Lyons, Roger, Koschmieder, Steffen, Rinaldi, Ciro, Byrne, Jennifer, Hasan, Yasmin, Passamonti, Francesco, Verstovsek, Srdan, Hunter, Deborah, Jones, Mark M., Zhen, Huiling, Habr, Dany, Martino, Bruno

Volltext

Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy von Mesa, Ruben, Verstovsek, Srdan, Kiladjian, Jean-Jacques, Griesshammer, Martin, Masszi, Tamas, Durrant, Simon, Passamonti, Francesco, Harrison, Claire N., Pane, Fabrizio, Zachee, Pierre, Zhen, Huiling, Jones, Mark M., Parasuraman, Shreekant, Li, Jingjin, Côté, Isabelle, Habr, Dany, Vannucchi, Alessandro M.

Volltext

Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide von Harrison, Claire N., Griesshammer, Martin, Miller, Carole, Masszi, Tamas, Passamonti, Francesco, Zachee, Pierre, Durrant, Simon, Pane, Fabrizio, Guglielmelli, Paola, Verstovsek, Srdan, Jones, Mark M., Hunter, Deborah S., Sun, William, Li, Jingjin, Khan, Mahmudul, Habr, Dany, Kiladjian, Jean‐Jacques

Volltext

Relationship between baseline white blood cell count and renal and hepatic function in older patients with acute myeloid leukemia von Delaunay, Jacques, Mazur, Grzegorz, Minden, Mark, Wierzbowska, Agnieszka, Jones, Mark M, Berrak, Erhan, Kantarjian, Hagop M

Volltext

Efficacy and safety of epacadostat plus pembrolizumab treatment of NSCLC: Preliminary phase I/II results of ECHO-202/KEYNOTE-037 von Gangadhar, Tara C., Schneider, Bryan J., Bauer, Todd Michael, Wasser, Jeffrey S., Spira, Alexander I., Patel, Sandip P., Balmanoukian, Ani Sarkis, Bauml, Joshua, Schmidt, Emmett V., Zhao, Yufan, Jones, Mark M., Tarhini, Ahmad A.

Volltext

Safety of epacadostat 100 mg bid plus pembrolizumab 200 mg Q3W in advanced solid tumors: Phase 2 data from ECHO-202/KEYNOTE-037 von Hamid, Omid, Bauer, Todd Michael, Spira, Alexander I., Smith, David C., Olszanski, Anthony J., Tarhini, Ahmad A., Lara, Primo, Gajewski, Thomas, Wasser, Jeffrey S., Patel, Sandip P., Borges, Virginia F., Balmanoukian, Ani Sarkis, Schmidt, Emmett V., Zhao, Yufan, Jones, Mark M., Gangadhar, Tara C.

Volltext

Post hoc analysis of the relationship between baseline white blood cell count and survival outcome in a randomized Phase III trial of decitabine in older patients with newly diagno... von Arthur, Christopher, Cermak, Jaroslav, Delaunay, Jacques, Mayer, Jiří, Mazur, Grzegorz, Thomas, Xavier, Wierzbowska, Agnieszka, Jones, Mark M, Berrak, Erhan, Kantarjian, Hagop

Volltext

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind st... von Long, Georgina V, Prof, Dummer, Reinhard, Prof, Hamid, Omid, MD, Gajewski, Thomas F, Prof, Caglevic, Christian, MD, Dalle, Stephane, Prof, Arance, Ana, MD, Carlino, Matteo S, PhD, Grob, Jean-Jacques, Prof, Kim, Tae Min, Prof, Demidov, Lev, Prof, Robert, Caroline, Prof, Larkin, James, Prof, Anderson, James R, PhD, Maleski, Janet, BSN, Jones, Mark, MD, Diede, Scott J, MD, Mitchell, Tara C, MD

Volltext

New Developments in Therapeutic Chelating Agents as Antidotes for Metal Poisoning von Jones, Mark M.

Volltext

In vivo studies of cadmium-induced apoptosis in testicular tissue of the rat and its modulation by a chelating agent von Xu, Cunyong, Johnson, Joyce E., Singh, Pramod K., Jones, Mark M., Yan, Heping, Carter, Clint E.

Volltext

Shedding light on electrodeposition dynamics tracked in situ via soft X-ray coherent diffraction imaging von Kourousias, George, Bozzini, Benedetto, Gianoncelli, Alessandra, Jones, Michael W. M., Junker, Mark, van Riessen, Grant, Kiskinova, Maya

Volltext

Mobilization of Iron by Chiral and Achiral Anionic 3-Hydroxypyrid-4-ones von Molenda, John Josef, Jones, Mark M, Johnston, David S, Walker, Ernest M, Cannon, Donald J

Volltext

Continued Treatment with Ruxolitinib Provides Additional Hematocrit Control and Spleen Volume Responses in Patients with PV Treated in the RESPONSE Study von Kiladjian, Jean-Jacques, Masszi, Tamás, Jones, Mark M., Gadbaw, Brian, Li, Jingjin, Habr, Dany, Vannucchi, Alessandro M., Verstovsek, Srdan

Volltext

Chelation of aluminium by combining DFO and L1 in rats von Blanuša, Maja, Prester, Ljerka, Varnai, Veda M., Pavlović, Draško, Kostial, Krista, Jones, Mark M., Singh, Pramod K.

Volltext

Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study von Long, Georgina V., Dummer, Reinhard, Hamid, Omid, Gajewski, Thomas, Caglevic, Christian, Dalle, Stéphane, Arance, Ana, Carlino, Matteo S., Grob, Jean-Jacques, Kim, Tae Min, Demidov, Lev V., Robert, Caroline, Larkin, James M. G., Anderson, James, Maleski, Janet E., Jones, Mark M., Diede, Scott J., Mitchell, Tara C.

Volltext

Ruxolitinib Efficacy By Hematocrit Control in Patients with Polycythemia Vera: An Analysis of the RESPONSE Trial von Verstovsek, Srdan, Kiladjian, Jean-Jacques, Mesa, Ruben, Jones, Mark M, He, Shui, Li, Jingjin, Habr, Dany, Vannucchi, Alessandro M.

Volltext

Efficacy of Ruxolitinib By Baseline Spleen Volume in Patients with Polycythemia Vera Resistant to or Intolerant of Hydroxyurea von Vannucchi, Alessandro M., Verstovsek, Srdan, Jones, Mark M, He, Shui, Li, Jingjin, Habr, Dany, Kiladjian, Jean-Jacques

Volltext

Chelation therapy in aluminum-loaded rats: influence of age von Gómez, Mercedes, Esparza, Jose L, Domingo, Jose L, Singh, Pramod K, Jones, Mark M

Volltext